In the BioHarmony Drug Report Database

"Preview" Icon

Copanlisib

Aliqopa (copanlisib) is a small molecule pharmaceutical. Copanlisib was first approved as Aliqopa on 2017-09-14. It is used to treat follicular lymphoma in the USA. It is known to target phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, serine/threonine-protein kinase mTOR, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform. Aliqopa’s patents are valid until 2032-03-29 (FDA).

 

Trade Name

 

Aliqopa
 

Common Name

 

copanlisib
 

ChEMBL ID

 

CHEMBL3218576
 

Indication

 

follicular lymphoma
 

Drug Class

 

Phosphatidylinositol 3-kinase inhibitors

Image (chem structure or protein)

Copanlisib structure rendering